Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

54 results about "Hepatic metastasis" patented technology

Colorectal carcinoma cell line CJF from hepatic metastasis and construction method thereof

The invention provides a colorectal carcinoma cell line CJF from hepatic metastasis and a construction method thereof. The obtaining method of the colorectal carcinoma cell line comprises the following steps: obtaining tissues of colorectal carcinoma hepatic metastasis; after digesting the tissues into single cells by using collagenase / hyaluronidase, separating and inoculating CD133+ cells under NOD (Non-Obese Diabetic) / SCID rat skin by MACS (magnetic-activated cell separation); nodulating, and taking out tumor tissues; and culturing in vitro to obtain the colorectal carcinoma cell line CJF which can stably passage and is rich in colorectal carcinoma stem cells. In the invention, CJF cells are obtained from hepatic metastasis of colonic carcinoma patients; compared with other colorectal carcinoma cell lines, the colorectal carcinoma cell line CJF has incomparable advantages for the study of the colonic carcinoma hepatic metastases; cell subsets of the CJF cells for stably expressing the CD133+ cells is about 10 percent; and the action and the research of the colorectal carcinoma cell line in a colorectal carcinoma hepatic metastases process and the tumor stem cells in a metastases mechanism have wide application prospects.
Owner:ZHEJIANG UNIV

Traditional Chinese medicinal composition for treating colon cancer hepatic metastases and preparation method thereof

The invention relates to a traditional Chinese medicinal composition for treating colon cancer hepatic metastases, which consists of the following raw material medicaments by weight: 3 to 9 grams of spreading hedyotis herb, 1,020 grams of golden thread, 20 to 40 grams of barbed skullcap herb, 20 to 40 grams of medlar, 5 to 20 grams of lightyellow sophora root, 5 to 20 grams of divaricate saposhnikovia root, 5 to 20 grams of bupleurum, 20 to 40 grams of swordlike atractylodes rhizome, 5 to 20 grams of large-headed atractylodes rhizome, 5 to 20 grams of dahurian patrinia herb, 20 to 40 grams of Indian iphigenia bulb, 20 to 40 grams of south dodder seed, 5 to 20 grams of black nightshade herb, 5 to 20 grams of ash bark, 20 to 40 grams of sargentodoxa stem, 20 to 40 grams of glossy privet fruit and 5 to 20 grams of amur corktree bark. The raw material medicaments are heated for extraction or diacolation in water or 30 to 90 percent ethanol, the material medicaments having been heated for the extraction or diacolation are purified to obtain extract, and then the extract is prepared into various preparations.
Owner:TIANJIN BIJIA PHARMA CO LTD

Screening and application of urine protein marker related to liver metastatic cancer

InactiveCN111426835ADisease diagnosisAnimal husbandryAntigenCathepsin H
The invention relates to screening and application of a urine protein marker related to liver metastatic cancer. Specifically, the present invention relates to a method for establishing an animal model for screening urine protein markers related to liver metastatic cancer. The invention also relates to application of the urine protein marker related to liver metastatic cancer obtained by the method in preparation of a kit for diagnosing liver metastatic cancer in a subject at an early stage. The urine protein marker is selected from one or more of parvalbumin alpha, annexin A1, a polymer immunoglobulin receptor, lysosome thioesterase (PPT2), cobalamin protein-2, a cathepsin H precursor, a galectin-3 binding protein, an HLA-I tissue compatible antigen, beta-2 microglobulin, vascular cell adhesion protein-1, complement C4, alpha-1-acid glycoprotein, or a combination thereof.
Owner:BEIJING NORMAL UNIVERSITY

Application of RFPL1S-201 in preparation of drugs for inhibiting proliferation, invasion and/or metastasis of ovarian cancer

The invention discloses application of RFPL1S-201 in the preparation of drugs for inhibiting the proliferation, invasion and / or metastasis of ovarian cancer, application of RFPL1S-201 or substances that promote the expression of RFPL1S-201 in the preparation of drugs for inhibiting the proliferation, invasion and / or metastasis of ovarian cancer, and application of expression plasmids overexpressing RFPL1S-201 in the preparation of drugs for inhibiting the proliferation, invasion and / or metastasis of ovarian cancer. It is found that lncRNA RFPL1S-201 can inhibit the proliferation, invasion andmetastasis of ovarian cancer cells, and meanwhile lncRNA RFPL1S-201 can inhibit the liver metastasis of ovarian cancer in vivo. A mechanism of action is mainly to inhibit tumor progression and promotetumor chemotherapy sensitivity by inhibiting an IFN-STAT1 signal channel.
Owner:NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL

Cucurbitacin B and oxidation-responsive antitumor prodrug co-loaded bionic nanoparticle

The invention belongs to the technical field of medicines, and relates to an exosome membrane-coated cucurbitacin B and oxidation-responsive antitumor prodrug co-loaded bionic nanoparticle, and an application thereof in the preparation of drugs for treating tumor metastasis diseases. The nanoparticle can ablate primary tumors and target circulating tumor cells so as to inhibit tumor metastasis. The exosome membrane-coated co-loaded bionic nanoparticle comprises 1-2 wt% of cucurbitacin B, 6-8 wt% of an oxidation-responsive antitumor prodrug, 60-70 wt% of a nano-carrier material, and the balanceof an exosome membrane, and the weight ratio of the cucurbitacin B to the oxidation-responsive antitumor prodrug is 1:4 to 1:8. The exosome membrane-coated cucurbitacin B and oxidation-responsive antitumor prodrug co-loaded bionic nanoparticle has an obvious effect of treating tumor metastasis, especially lung or liver metastasis of breast cancer, and can be used for preparing antitumor drugs.
Owner:SHENYANG PHARMA UNIVERSITY

Prediction model for survival benefit of metastatic kidney cancer patients after systematic treatment and an establishment method and application thereof

The invention belongs to the field of prognosis evaluation of metastatic kidney cancer patients, and particularly relates to a prediction model for survival benefit of metastatic kidney cancer patients after systematic treatment and an establishment method and application thereof. The prediction model for survival benefit of the metastatic kidney cancer patients after systematic treatment is a line chart model made by collecting time from primary diagnosis to systematic treatment of the metastatic kidney cancer patient, Karnofsky physical strength score, anemia, neutrophil polycythemia, thrombocythemia, hypercalcemia and bone / brain / liver metastasis, thereby predicting the time when the patient begins to receive system treatment to death. For a metastatic kidney cancer patient receiving systematic treatment, the actual condition of the influence variable in the column diagram can be scored, and the survival rate condition of the patient in the twelfth month and the twenty-fourth month can be obtained according to the corresponding position of the total column diagram, so that clinical doctors can use the survival rate in daily work more conveniently.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products